Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
AnaptysBio ( (ANAB) ) just unveiled an update.
On May 18, 2026, AnaptysBio, Inc.’s board of directors approved a shift in the company’s fiscal year-end from December 31 to June 30, with the next fiscal year set to begin on July 1, 2026. The company will file a transition Form 10-KT covering January 1 to June 30, 2026, and will thereafter report quarterly under the new fiscal calendar starting with the quarter ending September 30, 2026.
This change alters the company’s financial reporting cycle but does not directly affect its core operations, serving primarily to align its accounting periods with internal or strategic planning needs. Investors and other stakeholders will see a one-time transition reporting period, followed by a new cadence of quarterly disclosures that may influence how they track and compare AnaptysBio’s financial performance over time.
The most recent analyst rating on (ANAB) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on AnaptysBio stock, see the ANAB Stock Forecast page.
Spark’s Take on ANAB Stock
According to Spark, TipRanks’ AI Analyst, ANAB is a Neutral.
The score is driven by strong technical strength (clear uptrend with supportive momentum) but capped by mixed fundamentals—improving operations and cash generation offset by volatile TTM results and a weakened balance sheet. Valuation also weighs on the score due to continued net losses (negative P/E), while recent corporate actions are a moderate positive tailwind.
To see Spark’s full report on ANAB stock, click here.
More about AnaptysBio
AnaptysBio, Inc. is a biopharmaceutical company operating in the life sciences industry. It focuses on discovering and developing therapeutic antibodies, with a primary market focus on treating immune-mediated diseases and related indications in the healthcare sector.
Average Trading Volume: 634,932
Technical Sentiment Signal: Buy
Current Market Cap: $1.75B
Learn more about ANAB stock on TipRanks’ Stock Analysis page.